Abstract
The Oncotype DX Genomic Prostate Score® (GPS™) assay has been validated as a strong prognostic indicator of adverse pathology, biochemical recurrence, distant metastasis (DM), and prostate cancer (PCa)-related death (PCD) in men with localized PCa after radical prostatectomy. However, it has yet to be tested in men undergoing external beam radiation therapy (EBRT), for whom assessing PCa progression risk could inform decisions on treatment intensity. We analyzed whether GPS results are associated with time to biochemical failure (BCF), DM, and PCD after EBRT in men with localized PCa and whether the association is modified by race. We conducted a retrospective study of men with localized PCa treated with EBRT at the [ANONYMIZED FOR REVIEW] from 2000 to 2016. Study endpoints were time to BCF per the Phoenix criteria, DM, and PCD. The association of GPS results, per 20-unit increase or dichotomous variable (0-40 versus 41-100), was evaluated with each endpoint using univariable and multivariable Cox proportional hazards models. Results were then stratified by race. A total of 238 patients (69% Black) met eligibility criteria. Median follow-up for patients who did not experience BCF was 7.6 years. GPS results per 20-unit increase were significantly associated with BCF (hazard ratio (HR) 3.62; 95% CI 2.59, 5.02), DM (HR 4.48; 2.75, 7.38), and PCD (HR 5.36; 3.06, 9.76) in univariable analysis. GPS results remained significant in multivariable models adjusted for baseline clinical and pathological factors, with HRs similar to the univariable analysis. There was no significant interaction between the GPS assay and race (p=0.923). HRs for BCF were similar in Black men (3.88; 2.40, 6.24) versus non-Black men (4.01; 2.42, 6.45). Among men treated with EBRT, the GPS assay is a strong, independent prognostic indicator of time to BCF, DM and PCD, and performs similarly in Black and non-Black men.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
